[
  {
    "id": "D-2025-0007",
    "date": "2025-03-15",
    "companyA": "AstraZeneca",
    "companyB": "Genentech",
    "asset": "Anti-TROP2 ADC",
    "modality": "ADC",
    "indication": "TNBC",
    "stage": "Phase 2",
    "upfront": 250,
    "milestones": 750,
    "total": 1000
  },
  {
    "id": "D-2025-0006",
    "date": "2025-03-08",
    "companyA": "Merck",
    "companyB": "Seagen",
    "asset": "BCMA-targeted ADC",
    "modality": "ADC",
    "indication": "MM",
    "stage": "Phase 1",
    "upfront": 300,
    "milestones": 550,
    "total": 850
  },
  {
    "id": "D-2025-0005",
    "date": "2025-02-22",
    "companyA": "BMS",
    "companyB": "Gilead",
    "asset": "CD19/CD20 bsAb",
    "modality": "mAb",
    "indication": "DLBCL",
    "stage": "Phase 3",
    "upfront": 400,
    "milestones": 800,
    "total": 1200
  },
  {
    "id": "D-2025-0004",
    "date": "2025-02-14",
    "companyA": "Novartis",
    "companyB": "Kite Pharma",
    "asset": "CAR-T Platform",
    "modality": "Cell Therapy",
    "indication": "AML",
    "stage": "Approved",
    "upfront": 700,
    "milestones": 1400,
    "total": 2100
  },
  {
    "id": "D-2025-0003",
    "date": "2025-01-30",
    "companyA": "Pfizer",
    "companyB": "Moderna",
    "asset": "mRNA Cancer Vaccine",
    "modality": "mRNA",
    "indication": "NSCLC",
    "stage": "Preclinical",
    "upfront": 200,
    "milestones": 450,
    "total": 650
  },
  {
    "id": "D-2025-0002",
    "date": "2025-01-15",
    "companyA": "Roche",
    "companyB": "Blueprint Medicines",
    "asset": "RET Inhibitor",
    "modality": "Small Molecule",
    "indication": "NSCLC",
    "stage": "Phase 2",
    "upfront": 275,
    "milestones": 525,
    "total": 800
  },
  {
    "id": "D-2025-0001",
    "date": "2025-01-05",
    "companyA": "AstraZeneca",
    "companyB": "Daiichi Sankyo",
    "asset": "HER3-directed ADC",
    "modality": "ADC",
    "indication": "NSCLC",
    "stage": "Phase 1",
    "upfront": 350,
    "milestones": 850,
    "total": 1200
  },
  {
    "id": "D-2024-0042",
    "date": "2024-12-18",
    "companyA": "GSK",
    "companyB": "iTeos Therapeutics",
    "asset": "TIGIT mAb",
    "modality": "mAb",
    "indication": "NSCLC",
    "stage": "Phase 2",
    "upfront": 320,
    "milestones": 880,
    "total": 1200
  },
  {
    "id": "D-2024-0041",
    "date": "2024-12-10",
    "companyA": "Amgen",
    "companyB": "Adaptive Biotechnologies",
    "asset": "T-cell Receptor Platform",
    "modality": "Cell Therapy",
    "indication": "TNBC",
    "stage": "Preclinical",
    "upfront": 180,
    "milestones": 420,
    "total": 600
  },
  {
    "id": "D-2024-0040",
    "date": "2024-12-03",
    "companyA": "AbbVie",
    "companyB": "Immunogen",
    "asset": "CD123 ADC",
    "modality": "ADC",
    "indication": "AML",
    "stage": "Phase 1",
    "upfront": 230,
    "milestones": 570,
    "total": 800
  },
  {
    "id": "D-2024-0039",
    "date": "2024-11-28",
    "companyA": "J&J",
    "companyB": "Legend Biotech",
    "asset": "BCMA CAR-T",
    "modality": "Cell Therapy",
    "indication": "MM",
    "stage": "Phase 3",
    "upfront": 500,
    "milestones": 1100,
    "total": 1600
  },
  {
    "id": "D-2024-0038",
    "date": "2024-11-15",
    "companyA": "Takeda",
    "companyB": "Celsius Therapeutics",
    "asset": "IL-23 mAb",
    "modality": "mAb",
    "indication": "CRC",
    "stage": "Phase 1",
    "upfront": 150,
    "milestones": 450,
    "total": 600
  },
  {
    "id": "D-2024-0037",
    "date": "2024-11-07",
    "companyA": "Eli Lilly",
    "companyB": "Merus",
    "asset": "HER3/EGFR Bispecific",
    "modality": "mAb",
    "indication": "NSCLC",
    "stage": "Phase 2",
    "upfront": 280,
    "milestones": 820,
    "total": 1100
  },
  {
    "id": "D-2024-0036",
    "date": "2024-10-30",
    "companyA": "BMS",
    "companyB": "Repare Therapeutics",
    "asset": "ATR Inhibitor",
    "modality": "Small Molecule",
    "indication": "Ovarian",
    "stage": "Phase 1",
    "upfront": 200,
    "milestones": 600,
    "total": 800
  },
  {
    "id": "D-2024-0035",
    "date": "2024-10-22",
    "companyA": "Merck",
    "companyB": "Sutro Biopharma",
    "asset": "Folate Receptor Î± ADC",
    "modality": "ADC",
    "indication": "Ovarian",
    "stage": "Phase 2",
    "upfront": 300,
    "milestones": 900,
    "total": 1200
  }
]
